ABLYNX INITIATES PHASE I FOR ALX-0141 (ANTI-RANKL) GHENT, Belgium, 14 December 2009 - Ablynx [Euronext Brussels: ABLX]
announced today that it has initiated a double-blind, randomised,
placebo-controlled Phase I study with ALX-0141, a Nanobody® targeting
Receptor Activator of Nuclear Factor kappa B Ligand (RANKL), in
healthy postmenopausal women.
RANKL is involved in the production of osteoclasts, a type of cell
responsible for the destruction of bone (bone resorption). Under
normal physiological circumstances there ...
ABLYNX WILL RECEIVE FURTHER MILESTONE PAYMENTS OF ?3 MILLION AS PART
OF ITS STRATEGIC ALLIANCE WITH GHENT, Belgium, 2 December 2009 - Ablynx [Euronext Brussels: ABLX]
today announced that it will receive further milestone payments
totalling ?3 million from Boehringer Ingelheim, triggered as part of
its strategic alliance for the development and commercialisation of
Nanobodies®. Ablynx will now have earned a total of ?9 million in
milestone payments from Boehringer Ingelheim in 2009.
Ablynx and Boehringer Ingelheim entered into an agreement in
September 2007 to c ...
ABLYNX RECEIVES ?1.1 MILLION GRANT TO FURTHER DEVELOP NEW ROUTES OF
ADMINISTRATION FOR NANOBODIES® GHENT, Belgium, 23 November 2009 - Ablynx [Euronext Brussels: ABLX],
announced today that it has been awarded a grant worth ?1.1 million
by the Flemish agency for Innovation by Science and Technology (IWT).
The grant allows Ablynx to accelerate its development of alternative
routes of administration for therapeutic Nanobodies, and build on the
successes that have been achieved so far in this area. In December
2008, Ablynx concluded its first feasibility study of pulmonary
delivery ...
ABLYNX ACHIEVES THIRD MILESTONE IN DRUG DISCOVERY AND DEVELOPMENT
COLLABORATION GHENT, Belgium, 18 November 2009 - Ablynx [Euronext Brussels: ABLX],
announced today that it will receive an undisclosed milestone payment
from Novartis. The payment has been triggered by successful delivery
to Novartis of Nanobody® candidates which met specific criteria. This
will be the third milestone payment that Ablynx has received from
Novartis since the initiation of the alliance between the companies.
Novartis and Ablynx entered into the alliance in December 2005 to
discov ...
ABLYNX PROVIDES BUSINESS UPDATE FOR THE THIRD QUARTER 2009 REGULATED INFORMATION
GHENT, Belgium, 10 November 2009 - Ablynx [Euronext Brussels: ABLX]
today provides its non-audited business update in compliance with the
EU transparency directive. This report summarises material events and
Ablynx's financial position for the third quarter of 2009. It has
been approved by the Board of Directors.
Q3 2009 Highlights
* Initiated an open-label, randomised Phase II study of its
anti-thrombotic Nanobody®, ALX-0081, in patients undergoing
p ...
ABLYNX ANNOUNCES WARRANT EXERCISE GHENT, Belgium, 30 October 2009 - Ablynx [Euronext Brussels: ABLX]
today announced that an additional 4,407 common shares have been
issued by the Company in exchange for ?6,732.60 as the result of the
exercise of warrants by some employees and consultants of the
Company.
As a result of this transaction, Ablynx now has 36,889,789 shares
outstanding.
-ends-
About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com
Founded in 2001 in Ghe ...
ABLYNX WINS AWARD FOR 'MOST SUCCESSFUL EARLY PHASE TRIAL' GHENT, Belgium, 23 October 2009 - Ablynx [Euronext Brussels: ABLX] is
pleased to announce it has been awarded 'Most Successful Early Phase
Trial' at the 2009 Good Clinical Practice Journal's (GCPj) Clinical
Research Excellence Awards in London. The GCPj's Awards recognise
excellence in clinical research and development.
Commenting on the award, Chief Medical Officer Josi Holz said: "It is
a great honour to receive this prestigious award. We are pleased that
our lead programme, a nov ...
ABLYNX PROVIDES AN R&D UPDATE AND ANNOUNCES RECENT TECHNOLOGY
ADVANCES GHENT, Belgium, 19 October, 2009 - Ablynx [Euronext Brussels: ABLX],
announces that it will present an update of its therapeutic pipeline
and its recent advances with its Nanobody® technology platform at
Ablynx's R&D Update in Ghent today. The Company will also illustrate
the specific advantages of the Nanobody® platform compared with some
directly competing technologies.
Ablynx now has over 20 programmes in its therapeutic pipeline
including three Nanobodies® in ...
ABLYNX AND DOMANTIS SETTLE THEIR DISPUTE AND STOP THE ARBITRATION
PROCESS GHENT, Belgium, 12 October, 2009 - Ablynx [Euronext Brussels: ABLX],
today announced that it has reached a settlement with Domantis (part
of the GlaxoSmithKline group of companies) concerning an alleged
dispute relating to a settlement agreement which Ablynx and Domantis
entered into in 2005.
Under the new agreement Ablynx has received a license to the European
Winter II patent which lay at the heart of the dispute and in return
will pay Domantis low single-digit royalties on the ...
ABLYNX RECEIVES A SECOND MILESTONE PAYMENT FROM NANOBODY® DISCOVERY
AND DEVELOPMENT ALLIANCE GHENT, Belgium, 5 October 2009 - Ablynx [Euronext Brussels: ABLX],
announced today that it has received an undisclosed milestone payment
from Novartis for an exclusive research license in one of the
programmes that is a component of their ongoing Research and
Development alliance.
Novartis and Ablynx are collaborating to discover and develop
therapeutic Nanobodies® against targets that are difficult to address
with conventional antibodies and their fragments.
The ...
ABLYNX RECEIVES MILESTONE PAYMENT AS PART OF ITS STRATEGIC ALLIANCE
WITH BOEHRINGER INGELHEIM GHENT, Belgium, 1 October 2009 - Ablynx [Euronext Brussels: ABLX],
today announced that it will receive milestone payments totalling ?3
million from Boehringer Ingelheim triggered as part of its strategic
alliance for the development and commercialisation of Nanobodies®.
This is the second time Ablynx receives milestone payments from
Boehringer Ingelheim since the initiation of the strategic alliance
between the companies.
Ablynx and Boehringer Ingelheim entered into a ...
WYETH PHARMACEUTICALS INITIATES PHASE II AND PAYS ABLYNX ANOTHER
MILESTONE IN THE TNF-alpha NANOBODY Ghent, Belgium, 30 September 2009 - Ablynx [Euronext Brussels: ABLX],
today announced that it has reached a second milestone under the
terms of its collaboration with Wyeth Pharmaceuticals, a division of
Wyeth. A milestone payment of $4 million has been triggered by the
initiation by Wyeth of a first Phase II multiple dose study in
patients with rheumatoid arthritis (RA) for a Nanobody® targeting
tumour necrosis factor alpha (TNF-alpha).
Wyeth entered into a Phase I study in healthy volunte ...
DISCLOSURE IN ACCORDANCE WITH THE TRANSPARENCY LEGISLATION OF 2 MAY
2007 REGULATED INFORMATION
GHENT, Belgium, 24 September 2009 - Ablynx [Euronext Brussels: ABLX]
today announced, in accordance with Article 14 of the Belgian
Transparency Law, that Ablynx has received a notification with regard
to the participation in Ablynx NV of KBC Asset Management NV, having
its registered office at Havenlaan 2, 1080 Brussels.
As of 15 September 2009, KBC Asset Management NV manages, as a result
of a transfer of securities carrying voting rights, a participation
in ...
ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE UBS GLOBAL LIFE
SCIENCES CONFERENCE IN NEW YORK GHENT, Belgium, 15 September 2009 - Ablynx [Euronext Brussels: ABLX]
today announced that it will webcast its corporate presentation at
the UBS Life Sciences Conference on 22 September 2009 at 12.00 p.m.
EST / 6.00 p.m. CET. The conference is held Monday-Wednesday
September 21-23, 2009 at the Grand Hyatt New York in New York City.
The presentation will be hosted by Dr Edwin Moses, CEO and Chairman
at Ablynx. This will be webcasted live and may be accessed on the
home page ...
ABLYNX INITIATES PHASE II CLINICAL TRIAL FOR ALX-0081 GHENT, Belgium, 1 September 2009 - Ablynx [Euronext Brussels: ABLX]
today announced the initiation of a Phase II study for its
anti-thrombotic Nanobody® ALX-0081, a first-in-class Nanobody®
targeting von Willebrand Factor (vWF).
The open-label, randomized Phase II study is designed to evaluate the
safety and efficacy of multiple doses of ALX-0081 versus the
GPIIb/IIIa inhibitor ReoPro® in patients undergoing percutaneous
coronary intervention (PCI ...
ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2009 REGULATED INFORMATION
GHENT, Belgium, 27 August 2009 - Ablynx [Euronext Brussels: ABLX],
announced today its results for the six month period ending 30 June
2009, which have been prepared in accordance with the IAS 34 'Interim
Financial Reporting' as adopted by the European Union.
H1 2009 Highlights
* ?101.8 million in cash, cash equivalents and financial assets at
30 June 2009
* 93% increase in revenues to ?11.9 million (2008: ?6.2 million)
* Reported detailed positive Phase I ...
ABLYNX WILL ANNOUNCE HALF-YEAR RESULTS FOR 2009 WITH WEBCAST GHENT, Belgium, 24 August 2009 - Ablynx [Euronext Brussels: ABLX]
plans to announce its half-year results for 2009 on 27 August 2009
after market closure.
Dr Edwin Moses, CEO and Chairman of Ablynx, will host a conference
call webcast during which the half-year results for 2009 will be
presented, followed by a Q&A session. This event will be held on
Friday, 28 August 2009 at 3.00 p.m. CET.
The conference call will be webcast live and can be accessed through
the home page of the Ablynx webs ...
ABLYNX ANNOUNCES POSITIVE PHASE I RESULTS FOR SUBCUTANEOUS
ADMINISTRATION OF ITS ANTI-THROMBOTIC NAN GHENT, Belgium, 18 August 2009 - Ablynx [Euronext Brussels: ABLX]
today announced the positive results from its double-blind,
randomized, placebo-controlled, single and multiple dose Phase I
study with ALX-0681, a subcutaneous formulation of its novel
anti-thrombotic Nanobody® that selectively targets von Willebrand
factor (vWF). The positive Phase I data support the progression of
ALX-0681 towards Phase II testing in patients with thrombotic
thromb ...
Tagesgeld-Konditionen
Pressemitteilungen der Druckerei WIRmachenDRUCK finden Sie auf wir-machen-druck.de unter Aktuelles.
Tausende Kontaktanzeigen und Seitensprung Kontakte aus ganz Deutschland für diskrete Treffen
Hochwertiges und günstiges Spielzeug, sowie Bastelbedarf und Bastelmaterial gibt es im didagoshop.
Moderne Badmöbel und viele tolle Möbel für Ihr Zuhause.
Für ein effektives und erfolgreiches Direktmarketing. Adressen kaufen bei Best Adress.
Mit einem einfachen Strompreisvergleich können Sie jeden Monat sparen.
Günstige Kredite für Selbstständige und Freiberufler - auch in schwierigen Fällen!
Kfz Ersatzteile von 100Pro-Ersatzteile.de, Autoteile in Erstausrüsterqualität.
RSS Feed
